• Belite Bio filed marketing applications for tinlarebant to treat Stargardt disease type 1 in Singapore, the UK and Switzerland through Access Consortium.
• If authorized, tinlarebant would be the first approved treatment for the disease in those markets.
• U.S. and Japanese applications have been accepted for accelerated review; the U.S. target action date is February 12, 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Belite Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610141600PRIMZONEFULLFEED9845933) on October 14, 2026, and is solely responsible for the information contained therein.